Related references
Note: Only part of the references are listed.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Yunlong Cao et al.
NATURE (2022)
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
ShengLi Xia et al.
LANCET INFECTIOUS DISEASES (2022)
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
M. J. Joyner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Detection of a SARS-CoV-2 variant of concern in South Africa
Houriiyah Tegally et al.
NATURE (2021)
Sixteen novel lineages of SARS-CoV-2 in South Africa
Houriiyah Tegally et al.
NATURE MEDICINE (2021)
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Nicholas G. Davies et al.
SCIENCE (2021)
SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model
Jingxin Qiao et al.
SCIENCE (2021)
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Robert Challen et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann et al.
CELL (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Sandile Cele et al.
NATURE (2021)
Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil
Ronaldo da Silva Francisco Jr et al.
VIRUS RESEARCH (2021)
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Dan Fu et al.
PLOS BIOLOGY (2021)
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine
Xingdong Zhou et al.
PROTEIN & CELL (2021)
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Jianying Liu et al.
NATURE (2021)
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Cesheng Li et al.
NATURE COMMUNICATIONS (2021)
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
Katie L. Kunze et al.
NATURE COMMUNICATIONS (2021)
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
Baoying Huang et al.
LANCET MICROBE (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Convalescent plasma in Covid-19: Possible mechanisms of action
Manuel Rojas et al.
AUTOIMMUNITY REVIEWS (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate
Manuel Becerra-Flores et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2020)
Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?
Muthukrishnan Eaaswarkhanth et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Cell entry mechanisms of SARS-CoV-2
Jian Shang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
Janice Hopkins Tanne
BMJ-BRITISH MEDICAL JOURNAL (2020)
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Qianqian Li et al.
CELL (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
Jing Sun et al.
CELL (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
Jakob Kreye et al.
CELL (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Thomas F. Rogers et al.
SCIENCE (2020)
Treatment for emerging viruses: Convalescent plasma and COVID-19
Bethany L. Brown et al.
TRANSFUSION AND APHERESIS SCIENCE (2020)
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Alina Baum et al.
SCIENCE (2020)
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Edem Gavor et al.
TRENDS IN IMMUNOLOGY (2020)
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Jianhui Nie et al.
EMERGING MICROBES & INFECTIONS (2020)
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Plasma components: properties, differences, and uses
Richard John Benjamin et al.
TRANSFUSION (2012)
IGIV: Contents, properties, and methods of industrial production - evolving closer to a more physiologic product
TD Martin
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)